Report Library
All Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: HIV Treatment
January 04, 2021
The HIV treatment market in the US and five major European markets (France, Germany, Italy, Spain and the UK) is expected to continue to expand across the forecast period through to 2026, driven primarily by increases in disease prevalence and continued uptake of Gilead’s Biktarvy and ViiV Healthcare’s portfolio of two-drug regimens. Uptake of new premium-priced therapies (Rukobia and lenacapavir) in heavily treatment- experienced individuals will also drive growth, though their impact will be limited by the relatively low number of patients in the salvage setting. However, a plethora of products undergoing patent expiry across the forecast period will tip the market into decline from 2027, particularly Descovy, which is the preferred nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone, as physicians and payers will be provided with the ability to construct lower-cost once-daily regimens with generic Descovy and a generic third antiretroviral agent (such as dolutegravir, which will lose exclusivity in the US in 2027).
This Datamonitor Healthcare report contains a Disease Analysis module.
Indications Covered: | HIV / AIDS |